Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia

Research output: Contribution to journalReview article


Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from an human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose post transplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.

Original languageEnglish (US)
Pages (from-to)629-642
Number of pages14
JournalHematology/Oncology Clinics of North America
Issue number4
StatePublished - Aug 2018


  • Cyclophosphamide
  • Graft versus host disease
  • Haploidentical transplant
  • Severe aplastic anemia

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia'. Together they form a unique fingerprint.

  • Cite this